Transgenic mice over-expressing either Pim-1 or Pim-2 are predisposed to T cell lymphomas, whereas both Pim-1 and Pim-2 act synergistically with c-Myc to accelerate development of B-cell tumors [2], [4]–[6]. Here, PIM2 is linked to T-cell non-Hodgkin lymphoma.